Important considerations for treatment with dietary supplement versus prescription niacin products

Postgraduate Medicine

Volumn 123, Issue 2, 2011, Pages 70-83

  Backes, James M ^a   Padley, Robert J ^b   Moriarty, Patrick M ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Dietary supplement; Dyslipidemia; Flush free niacin; Niacin extended release

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BILE ACID; COLESTIPOL; CREATINE KINASE; ENDUR ACIN; EZETIMIBE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INOSITOL NICOTINATE; LAROPIPRANT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; QUERCETIN; RESIN; SIMVASTATIN; SLO NIACIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTERIAL WALL THICKNESS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; FLUSHING; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GOOD MANUFACTURING PRACTICE; GOUT; GOVERNMENT REGULATION; HEART PROTECTION; HEARTBURN; HEPATITIS LIKE SYNDROME; HOT FLUSH; HUMAN; HYPERURICEMIA; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; METABOLIC DISORDER; MUSCLE DISEASE; MYALGIA; MYOPATHY; NAUSEA; PAIN; PATIENT COMPLIANCE; PEPTIC ULCER; PRESCRIPTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SKIN REDNESS; SKIN TINGLING; THROMBOSIS; URIC ACID BLOOD LEVEL; VASODILATATION; VOMITING;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DIETARY SUPPLEMENTS; DYSLIPIDEMIAS; FLUSHING; HUMANS; LIVER; NIACIN; PRESCRIPTION DRUGS; TRIGLYCERIDES;

EID: 79955109060     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.03.2265     Document Type: Article

References (130)

1. Baigent C, Keech A, Kearney PM, etal; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
2. Colhoun HM, Betteridge DJ, Durrington PN, etal. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
3. Downs JR, Clearfield M, Weis S, etal. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622.
4. Neil HA, DeMicco DA, Luo D, etal; CARDS Study Investigators. Analysis of efficacy and safety in patients aged 65-75years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes Care. 2006;29(11):2378-2384.
5. Sacks FM, Pfeffer MA, Moye LA, etal. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335(14):1001-1009.
6. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645-654; discussion 653-654.
7. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-1357.
8. Shepherd J, Cobbe SM, Ford I, etal; West of Scotland Cornary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. 1995. Atheroscler Suppl. 2004;5(3):91-97.
9. Fruchart JC, Sacks F, Hermans MP, etal. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102(10suppl):1K-34K.
10. Cannon CP. High-density lipoprotein cholesterol and residual cardiometabolic risk in metabolic syndrome. Clin Cornerstone. 2007;8(suppl 6):S14-S23.
11. National cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
12. Chapman MJ. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther. 2005;19(2):135-139.
13. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med. 2007;356(3):213-215.
14. Barter P, Gotto AM, LaRosa JC, etal. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301-1310.
15. Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003;18(4):278-285.
16. Cannon CP. Combination therapy in the management of mixed dyslipidaemia. J Intern Med. 2008;263(4):353-365.
17. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256(20):2835-2838.
18. Gordon DJ, Probstfield JL, Garrison RJ, etal. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79(1):8-15.
19. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298(7):786-798.
20. Marcil M, O'Connell B, Krimbou L, Genest J Jr. High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Rev Cardiovasc Ther. 2004;2(3):417-430.
21. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164(7):697-705.
22. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007;100(11A):n32-n40.
23. Clarke R, Peden JF, Hopewell JC, etal; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-2528.
24. Kathiresan S. Lp(a) lipoprotein redux-from curious molecule to causal risk factor. N Engl J Med. 2009;361(26):2573-2574.
25. Chapman MJ, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis. Atherosclerosis. 1994;110(suppl):S69-S75.
26. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther. 2010;126(3):314-345.
27. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation. 2000;102(10):1082-1085.
28. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001;88(3):270-274.
29. Jafri H, Karas RH, Kuvin JT. Effects of niacin on LDL particle number. Clin Lipidology. 2009;4(5):565-571.
30. Canner PL, Berge KG, Wenger NK, etal. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245-1255.
31. Brown G, Albers JJ, Fisher LD, etal. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289-1298.
32. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257(23):3233-3240.
33. Cashin-Hemphill L, Mack WJ, Pogoda JM, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA. 1990;264(23):3013-3017.
34. Taylor AJ, Villines TC, Stanek EJ, etal. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med. 2009;361(22):2113-2122.
35. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin. 2006;22(11):2243-2250.
36. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004;110(23):3512-3517.
37. Villines TC, Stanek EJ, Devine PJ, etal. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010;55(24):2721-2726.
38. McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs. 2005;65(18):2719-2740.
39. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 1998.
40. Jacobson TA. A "hot" topic in dyslipidemia management-"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention. Mayo Clin Proc. 2010;85(4):365-379.
41. Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol. 2000;86(12A):35L-40L.
42. Miller ON, Hamilton JG, Goldsmith GA. On the mechanism of action of nicotinic acid in lowering serum lipids. Am J Clin Nutr. 1962;10:285-296.
43. Council for Responsible Nutrition. Hathcock JN, ed. Niacin: nicotinic acid and nicotinamide. In: Vitamin and Mineral Safety. 2nd ed. Washington, DC: Council for Responsible Nutrition; 2004.
44. Niacor (niacin) [package insert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc; 2008.
45. Benyo Z, Gille A, Bennett CL, Clausen BE, Offermanns S. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol. 2006;70(6):1844-1849.
46. Kamanna VS, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009;63(9):1369-1377.
47. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract. 2006;60(6):707-715.
48. Thakkar RB, Kashyap ML, Lewin AJ, Krause SL, Jiang P, Padley RJ. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs. 2009;9(2):69-79.
49. Kalogeromitros D, Makris M, Chliva C, Aggelides X, Kempuraj D, Theoharides TC. A quercetin containing supplement reduces niacin-induced flush in humans. Int J Immunopathol Pharmacol. 2008;21(3):509-514.
50. Maccubbin D, Bays HE, Olsson AG, etal. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract. 2008;62(12):1959-1970.
51. Goldberg A, Alagona P Jr, Capuzzi DM, etal. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol. 2000;85(9):1100-1105.
52. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol. 1998;82(12A):29U-34U; discussion 39U-41U.
53. Grundy SM, Vega GL, McGovern ME, etal; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med. 2002;162(14):1568-1576.
54. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2005;95(2):254-257.
55. Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc. 2003;78(6):735-742.
56. Capuzzi DM, Morgan JM, Brusco OA Jr, Intenzo CM. Niacin dosing: relationship to benefits and adverse effects. Curr Atheroscler Rep. 2000;2(1):64-71.
57. ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists. Am J Health Syst Pharm. 1997;54(24):2815-2819.
58. Mills E, Prousky J, Raskin G, etal. The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]. BMC Clin Pharmacol. 2003;3:4.
59. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231(4):360-381.
60. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6A):22C-31C.
61. Niaspan (niacin tablet, extended release) [package insert]. North Chicago, IL: Abbott Laboratories; 2007.
62. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150(12):858-868.
63. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36(2):288-295.
64. US Food and Drug Administration. Overview of dietary supplements. http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/ucm110417.htm. Accessed September 10, 2010.
65. Dietary Supplement Health and Education Act of 1994. http://www.health.gov/dietsupp/ch1.htm. Accessed September 10, 2010.
66. US Food and Drug Administration. FDA 101: dietary supplements. http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm050803.htm. Accessed September 10, 2010.
67. US Food and Drug Administration. Adverse Event Reporting System (AERS). http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm. Accessed September 10, 2010.
68. US Food and Drug Administration. Adverse drug experience reporting. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm082056.htm. Accessed September 10, 2010.
69. US Food and Drug Administration. Claims that can be made for conventional foods and dietary supplements. http://www.fda.gov/Food/LabelingNutrition/LabelClaims/ucm111447.htm. Accessed September 10, 2010.
70. US Food and Drug Administration. Major issues and recommendations related to the labeling of dietary supplements. http://www.health.gov/dietsupp/ch3.htm. Accessed September 10, 2010.
71. US Food and Drug Administration. Guidance for industry: evidence-based review system for the scientific evaluation of health claims-final. http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/ucm073332.htm. Accessed September 10, 2010.
72. National Institutes of Health. Dietary supplements: background information. http://ods.od.nih.gov/factsheets/dietarysupplements.asp. Accessed September 10, 2010.
73. Troppmann L, Gray-Donald K, Johns T. Supplement use: is there any nutritional benefit? J Am Diet Assoc. 2002;102(6):818-825.
74. American Heart Association. Cholesterol-lowering drugs. http://www.americanheart.org/presenter.jhtml?identifier=4510. Accessed September 10, 2010.
75. Gray DR, Morgan T, Chretien SD, Kashyap ML. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med. 1994;121(4):252-258.
76. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA. 1994;271(9):672-677.
77. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185-197.
78. Swanson Vitamins. Flush-free niacin. http://www.swansonvitamins.com/SWU080/ItemDetail. Accessed September 10, 2010.
79. Sundown Natural. Flush free niacin 500mg capsules. http://www.sundownnaturals.com/products/product.aspx?UPC=030768037871. Accessed September 10, 2010.
80. Nature's Bounty. Niacin. http://www.naturesbounty.com/vf/labels/001976NB.pdf. Accessed September 10, 2010.
81. Schiff. Niacin (flush free). http://www.schiffvitamins.com/product_detail.asp?id=15#. Accessed September 10, 2010.
82. Puritan's Pride. Flush Free Niacin 1000mg. http://www.puritan.com/niacin-b-3-362/flush-free-niacin-inositol-nicotinate-1000-mg-015482?NewPage=1#product. Accessed September 10, 2010.
83. Source Naturals. No-Flush Niacin. http://www.sourcenaturals.com/products/GP1447/. Accessed September 10, 2010.
84. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med. 2003;139(12):996-1002.
85. Poon IO, Chow DS, Liang D. Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. Am J Health Syst Pharm. 2006;63(21):2128-2134.
86. Dorner G, Fischer FW. [On the modification of serum lipids and lipoproteins by the hexanicotinic acid ester of m-inositol]. Arzneimittelforschung. 1961;11:110-113.
87. Welsh AL, Ede M. Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report. Int Rec Med. 1961;174:9-15.
88. Agusti R, Jordan C, Aste H, Tapia F. [Effect of hexanicotinate of meso-inositol in patients with primary hyperlipidemia (author's transl)]. Rev Invest Clin. 1978;30(4):327-335.
89. Kruse W, Kruse W, Raetzer H, etal. Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives. Eur J Clin Pharmacol. 1979;16(1):11-15.
90. Ziliotto GR, Lamberti G, Wagner A, Cima L, Genco G. [Comparative studies of the response of normolipemic and dyslipemic aged subjects to 2 forms of delayed-action nicotinic acid polyesters. Pentaerythrotol tetranicotinate and inositol hexanicotinate. Results of a controlled cross-over trial]. Arch Sci Med (Torino). 1977;134(4):359-394.
91. El-Enein AMA, Hafez YS, Salem H, Abdel M. The role of nicotinic acid and inositol hexaniocotinate as anticholesterolemic and antilipemic agents. Nutrition Reports International. 1983;28:899-911.
92. Norris RB. "Flush-free niacin": dietary supplement may be "benefit-free". Prev Cardiol. 2006;9(1):64-65.
93. Keenan JM. Sustained-release nicotinic acid vs inositol hexanicotinate for the treatment of dyslipidemia [Abstract P153]. Arterioscler Thromb Vasc Biol. 2008:e-61-e-62.
94. Aronov DM, Keenan JM, Akhmedzhanov NM, Perova NV, Oganov RY, Kiseleva NY. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5(10):567-575.
95. Keenan JM, Bae CY, Fontaine PL, etal. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc. 1992;40(1):12-18.
96. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151(7):1424-1432.
97. Knopp RH, Retzlaff BM, Fish B, etal. The SLIM Study: Slo-Niacin(R) and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. J Clin Lipidol. 2009;3(3):167-178.
98. Brown BG, Zhao XQ, Chait A, etal. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345(22):1583-1592.
99. Coppola A, Brady PG, Nord HJ. Niacin-induced hepatotoxicity: unusual presentations. South Med J. 1994;87(1):30-32.
100. Dalton TA, Berry RS. Hepatotoxicity associated with sustained-release niacin. Am J Med. 1992;93(1):102-104.
101. Etchason JA, Miller TD, Squires RW, etal. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. Mayo Clin Proc. 1991;66(1):23-28.
102. Lawrence SP. Transient focal hepatic defects related to sustained-release niacin. J Clin Gastroenterol. 1993;16(3):234-236.
103. US Food and Drug Administration. Code of Federal Regulations Title 21. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=314.80. Accessed September 10, 2010.
104. Knopp RH, Alagona P, Davidson M, etal. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism. 1998;47(9):1097-1104.
105. Simcor (simvastatin/niacin extended-release) [package insert]. North Chicago, IL: Abbott Laboratories; 2010.
106. Advicor (lovastatin/niacin extended-release) [package insert]. North Chicago, IL: Abbott Laboratories; 2010.
107. Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21(3):221-225.
108. Alsheikh-Ali AA, Karas RH. The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am J Cardiol. 2008;101(8A):9B-13B.
109. American Heart Association. Cholesterol medications. http://www.americanheart.org/presenter.jhtml?identifier=3044771#four. Accessed September 10, 2010.
110. American Pharmacists Association. American Heart Associations updates niacin guidelines. http://www.pharmacist.com/AM/Template.cfm?Section=Home2&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=11154. Accessed February 12, 2010.
111. US Food and Drug Administration. Prescription drugs and over-the-counter (OTC) drugs: questions and answers. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100101.htm. Accessed September 10, 2010.
112. US Food and Drug Administration. Postmarket requirements and commitments. http://www.fda.gov/Drugs/InformationOnDrugs/ucm142931.htm. Accessed September 10, 2010.
113. US Pharmacopeia. The regulation of dietary supplements. www. usp.org/pdf/EN/USPVerified/dietarySupplementRegulation.pdf. Accessed September 10, 2010.
114. Davignon J, Roederer G, Montigny M, etal. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol. 1994;73(5):339-345.
115. Morgan JM, Capuzzi DM, Baksh RI, etal. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol. 2003;91(12):1432-1436.
116. Goldberg AC. Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study. Am J Cardiol. 1998;82(12A):35U-38U; discussion 39U-41U.
117. Kuvin JT, Rämet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144(1):165-172.
118. Brown BG, Bardsley J, Poulin D, etal. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol, 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol. 1997;80(2):111-115.
119. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264(6):723-726.
120. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. Am J Med. 1994;97(4):323-331.
121. Elam MB, Hunninghake DB, Davis KB, etal. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA. 2000;284(10):1263-1270.
122. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol. 1997;79(9):1298-1301.
123. Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med. 1994;154(1):73-82.
124. Wink J, Giacoppe G, King J. Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy. Am Heart J. 2002;143(3):514-518.
125. O'Kane MJ, Trinick TR, Tynan MB, Trimble ER, Nicholls DP. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. Br J Clin Pharmacol. 1992;33(4):451-453.
126. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of prava-statin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 1995;76(7):480-484.
127. Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20mg) and nicotinic acid (1.2g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 1995;76(3):182-184.
128. Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with "isolated" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol. 1992;69(12):1083-1085.
129. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev. 1999;79(4):1193-1226.
130. Yiu KH, Cheung BM, Tse HF. A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin. Expert Opin Investig Drugs. 2010;19(3):437-449.